Back to top
more

Masimo (MASI)

(Real Time Quote from BATS)

$105.75 USD

105.75
138,884

-2.34 (-2.17%)

Updated Jul 30, 2024 01:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (105 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Catalent (CTLT) Expands Packaging Capabilities at Japan Facility

Catalent's (CTLT) latest capability expansion is expected to boost its business in this key hub in its Asia-Pacific Clinical Supply Services network.

Here's Why You Should Retain Integer Holdings (ITGR) Stock Now

Integer Holdings (ITGR) continues to gain momentum from improving non-medical sales and a solid foothold in the broader MedTech space. However, intense competition persists.

Cardinal Health (CAH) Ties Up to Deliver Products Via Drones

Cardinal Health's (CAH) latest collaboration is expected to significantly boost its distribution strategy and improve patient service.

3 Reasons to Retain Catalent (CTLT) Stock in Your Portfolio

Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism about the stock.

Omnicell (OMCL) Up 10% Since Q1 Earnings: What's Driving It?

Investors are optimistic about Omnicell's (OMCL) strategic partnerships and continued innovations for the Autonomous Pharmacy.

Here's Why You Should Retain PerkinElmer (PKI) Stock Now

PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.

Patterson Companies (PDCO) Q4 Earnings Beat, Revenues Up Y/Y

Patterson Companies' (PDCO) fiscal fourth-quarter 2022 results benefit from strength in the Dental and Animal Health segments.

Align (ALGN) Gains From Increased Case Shipment Amid FX Woes

Align Technology's (ALGN) focus on expanding its global operations, both in existing and emerging international markets, raises optimism.

Charles River (CRL) Signs saRNA-Based Vaccine Manufacture Deal

Charles River's (CRL) industry knowledge in plasmid DNA production will benefit Ziphius Vaccines' early-stage saRNA manufacturing program.

Here's Why Investors Should Retain Syneos Health (SYNH) For Now

Investors about optimistic about Syneos Health's (SYNH) robust segmental performance and earnings outlook.

3 Reasons to Add Masimo (MASI) Stock to Your Portfolio Now

Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.

Amedisys' (AMED) New Tie Up to Boost At-Home Patient Care

Amedisys (AMED) strengthens its Home Health and Hospice business reach by partnering with Memorial Hermann.

Here's Why You Should Retain AngioDynamics (ANGO) Stock Now

AngioDynamics (ANGO) continues to benefit from strength in segments, but forex remains a woe.

Stryker (SYK) to Boost Presence in China Via Digital Healthcare

Stryker's (SYK) participation at the WIC in China marks a milestone for the company as it can bring more Advanced Digital Healthcare solutions to the China market.

Here's Why Investors Should Retain CVS Health (CVS) For Now

Investors are optimistic about CVS Health's (CVS) robust revenue growth across its operating segments.

Reasons to Retain Allscripts (MDRX) Stock in Your Portfolio

Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances.

Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now

Myriad Genetics (MYGN) continues to benefit from strong testing volumes, but forex remains a woe.

Here's Why You Should Invest in AMN Healthcare (AMN) Stock Now

AMN Healthcare (AMN) continues to benefit from its broad range of services.

3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio

Investors continue to be optimistic about Nevro (NVRO) owing to its strength in the global SCS market.

Change Healthcare (CHNG)-Luma Launch Patient Engagement Suite

Change Healthcare's (CHNG) latest launch is expected to significantly improve patients' healthcare journey and create a more streamlined patient experience.

Here's Why You Should Retain Patterson Companies (PDCO) Stock

Patterson Companies (PDCO) continues to benefit from its strength in the Animal Health business and robust product portfolio. However, stiff competition remains a woe.

BD (BDX) Integrates Innovative Solution to Boost Patient Care

BD's (BDX) announcement of the implementation of BD HealthSight brings together timely monitoring to support the early detection of emerging healthcare infections, thereby improving patient care.

Here's Why You Should Hold on to Inogen (INGN) Stock For Now

Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.

PerkinElmer (PKI) Unveils GC Platform to Simplify Lab Operations

PerkinElmer's (PKI) newly introduced next-generation, automated GC platform can help simplify lab operations and offer excellent precision for high throughput environments.

Here's Why You Should Retain Inari Medical (NARI) Stock Now

Inari Medical (NARI) continues to benefit from its commitment toward understanding the venous system. However, dependency on the wide adoption of products is a woe.